Hengrui Liu

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 6

Top Topics

Respiratory Syndrome Coronavirus

Top Venues

Nature communications

Nature chemical biology

Life science alliance

This page only lists publications with an associated author ORCID identifier.

Publications

Judith Michels, Divya Venkatesh, Cailian Liu, Sadna Budhu, Hong Zhong, Mariam M George, Daniel Thach, Zhong-Ke Yao, Ouathek Ouerfelli, Hengrui Liu, Brent R Stockwell, Luis Felipe Campesato, Dmitriy Zamarin, Roberta Zappasodi, Jedd D Wolchok, Taha Merghoub
APR-246 increases tumor antigenicity independent of p53. Life science alliance 7 (1) (2023)
Hengrui Liu, Sho Iketani, Arie Zask, Nisha Khanizeman, Eva Bednarova, Farhad Forouhar, Brandon Fowler, Seo Jung Hong, Hiroshi Mohri, Manoj S Nair, Yaoxing Huang, Nicholas E S Tay, Sumin Lee, Charles Karan, Samuel J Resnick, Colette Quinn, Wenjing Li, Henry Shion, Xin Xia, Jacob D Daniels, Michelle Bartolo-Cruz, Marcelo Farina, Presha Rajbhandari, Christopher Jurtschenko, Matthew A Lauber, Thomas McDonald, Michael E Stokes, Brett L Hurst, Tomislav Rovis, Alejandro Chavez, David D Ho, Brent R Stockwell
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nature communications 13 (1) (2022)
Sho Iketani, Farhad Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Manoj S Nair, Arie Zask, Yaoxing Huang, Li Xing, Brent R Stockwell, Alejandro Chavez, David D Ho
Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nature communications 12 (1) (2021)
Sho Iketani, Farhad Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Manoj S Nair, Arie Zask, Yaoxing Huang, Li Xing, Brent R Stockwell, Alejandro Chavez, David D Ho
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nature communications 12 (1) (2021)
Hengrui Liu, Farhad Forouhar, Tobias Seibt, Russell Saneto, Kristen Wigby, Jennifer Friedman, Xin Xia, Mikhail S Shchepinov, Sanath Kumar Ramesh, Marcus Conrad, Brent R Stockwell
Characterization of a patient-derived variant of GPX4 for precision therapy. Nature chemical biology 18 (1) (2021)
Hengrui Liu, Stuart L Schreiber, Brent R Stockwell
Targeting Dependency on the GPX4 Lipid Peroxide Repair Pathway for Cancer Therapy. Biochemistry 57 (14) (2018)